post-transplant lymphoproliferative disorder after liver transplantation
Conditions
Interventions
EBV positive PTLD treatment group:Stratified treatment with rituximab
Sponsors
Beijing Friendship Hospital ,Capital Medical University
Eligibility
Sex/Gender
All
Age
1 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The patient or their legal guardian has signed the informed consent form; 2. EBV-DNA in peripheral blood or plasma > 500 copies/ml; 3. Lymphoid tissue pathology clearly diagnoses early lesions of PTLD, polymorphic PTLD, and CD20+ monomorphic PTLD (DLBCL); 4. Positive for EBER in situ hybridization.
Exclusion criteria
Exclusion criteria: 1. CD20- monomorphic PTLD, classical Hodgkin lymphoma, and primary central nervous system lymphoma; 2. Presence of active hepatitis B virus infection; 3. Inability to comply with the study protocol for treatment and specimen collection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response time to treatment;Treatment response rate;survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of infection;treatment related mortality;The incidence of graft rejection;The incidence of graft loss; | — |
Countries
China
Contacts
Public ContactYing Liu
Beijing Friendship Hospital ,Capital Medical University
Outcome results
None listed